The Centers for Medicare & Medicaid Services late today issued a proposed rule to update skilled nursing facility payment rates for fiscal year 2022. The rule would update payments by a net 1.3% relative to FY 2021 ($444 million), which includes a 2.3% market basket, a 0.2 percentage point productivity reduction and a forecast error adjustment to account for prior overpayment. CMS also would update the diagnosis code mappings used in the case-mix system implemented in FY 2021, and rebase and revise the SNF market basket. 

CMS also proposes to adopt two new quality measures beginning in FY 2023. One would assess the rate of COVID-19 vaccination among health care personnel, and the other would calculate healthcare-associated infections acquired in SNFs based on claims for subsequent hospitalizations. For the SNF Value-based Purchasing program, CMS proposes to suppress data for the single measure used in that program due to the impact of the COVID-19 pandemic, and instead will issue a uniform 1.2% payback percentage to participating SNFs with sufficient case volume rather than determining payment adjustments based on performance.

Comments on this rule are due to CMS by June 7.
 

Related News Articles

Headline
The Department of Health and Human Services Health Resources and Services Administration is accepting applications until April 22 for its four-year Rural…
Headline
The AHA today urged the Medicare Payment Advisory Commission to update payment recommendations for hospitals, post-acute care facilities and physicians in…
Headline
The AHA's Advancing Health podcast recently celebrated the end of 2024 by releasing highlights from some of its most popular episodes of the year. The roundup…
Headline
The Centers for Medicare & Medicaid Services Dec. 20 solicited an additional 10 participants for its Rural Community Hospital Demonstration program. This…
Headline
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA…
Headline
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…